Johnson & Johnson beat Wall Street’s expectations for first-quarter profit and revenue on Tuesday, as strong growth in the U.S. offset weakness internationally. The medical-technology and drug company raised its outlook for full-year sales but kept its profit guidance intact.

The costs will be felt primarily within the company’s medical technology unit, which makes a range of medical devices and surgical products.

Johnson & Johnson (JNJ) on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full year. The pharmaceutical and medical technology firm posted adjusted earnings per share (EPS) of $2.